Key takeaways
Tremfya (guselkumab) and Dupixent (dupilumab) are both injectable medications used to treat different inflammatory conditions, but they have some key differences. Tremfya is specifically approved for moderate-to-severe plaque psoriasis and active psoriatic arthritis, while Dupixent is used for a wider range of conditions, including eczema, asthma, sinus congestion with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. Tremfya works by blocking the IL-23 protein to reduce inflammation, whereas Dupixent blocks multiple proteins responsible for inflammation. Tremfya is typically injected every 8 weeks after the initial doses, while Dupixent's dosing varies from weekly to monthly depending on the condition being treated. Tremfya is only available as a brand-name medication, making it potentially more expensive, whereas Dupixent also lacks a generic form. Both medications can cause injection site reactions and increase the risk of infections, but Dupixent is more likely to cause eye inflammation and has a broader range of side effects.
